sugemalimab
cstone pharmaceuticals,eqrx
['nsclc', '9027', 'sclc', 'eqrx']
at #asco22: new overall survival data of our investigational anti-pd-l1 therapy for stage iv #nsclc. see why we re working to couple scientific innovation with pricing innovation to increase patient access globally. abstract #9027: 
EQRx is a new type of pharmaceutical company committed to developing & delivering innovative medicines to patients at RADICALLY lower prices. #RemakingMedicine